On 1 October 2026, Episurf Medical AB (publ) ("Episurf") issued, in relation to the closing of the acquisition of the Hudiksvall portfolio, convertibles in an aggregated nominal amount of SEK 64,780,000. Convertibles in a nominal amount of SEK 9,279,911 have, as of the date of this press release, at the request from holders of convertible debentures, been converted into 206,220,244 Class B shares in Episurf at a conversion price of SEK 0.045 per share in accordance with the terms and conditions.
Through the conversion, the number of Class B shares and votes in Episurf increases by 206,220,244, corresponding to a dilution effect of approximately 1.27 per cent of the shares and the votes respectively. Through the conversion, the share capital increases by SEK 2,062,202.44.
For further details, please contact:
Jens Andersson, CEO, Episurf Medical
Tel: +46 (0) 768 55 67 02
Email: jens.andersson@episurf.se
The information was submitted for publication, through the agency of the contact person set out above, at 18:00 CEST on 7 October 2026.
About Episurf Medical AB
Episurf Medical is a property company with exposure to a diversified portfolio of property assets. The Company's objective is to create value growth through the acquisition and management of Nordic properties. The Company also has a medical technology business based on the individualised Episealer® implant and associated surgical instruments, which are used to treat cartilage damage in joints. Episurf Medical's head office is located in Stockholm, Sweden.